Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Speedel Group

Division of Novartis AG

Latest From Speedel Group

Biotech Models: Bypassing VCs to Deal Direct with Pharma

There has to be a better way to do biotech than lurching from one hard-fought VC round to the next, losing sight of product development for the sake of providing an exit for investors. That's the view of HS LifeSciences, which aims to create a more direct route from promising academic research to market, avoiding the management time, heartache and dilution associated with serial VC rounds. Put simply, the idea is to match innovative technologies or research projects with potential pharma partners very early on, bypassing VC funding and allowing maximum resource and attention to be focused on the product.
BioPharmaceutical Business Strategies

Vitae's Debt Financing: Crucial Lifeline in a Tightening Financial Market

Roughly one week after GlaxoSmithKline gave Vitae Pharmaceuticals back rights to its renin inhibitor, the biotech signed a $13 million loan deal with Silicon Valley Bank and Oxford Finance, providing a cash runway at least into 2010. The cash lifeline was relatively small in dollar value but significant for even happening in the first place. The hard economic times have all but shut down the venture capital supply, leaving serious questions about money strategies for other biotechs.

Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?

The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
BioPharmaceutical Strategy

Corporate VC Adds a Business Development Flavor

Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Konrad P Wirz, CFO
    Michael Merz, Head, Clinical R&D
    Ben Tan, Dir., Bus. Dev. & Licensing
  • Contact Info
  • Speedel Group
    Phone: (41) 61 206 40 00
    Hirschgässlein 11
    Basel, CH-4051